Scholar Rock Reports Wider Q4 Loss, Focus Remains on Apitegromab Approval
SCHOLAR ROCK HOLDING CORP (NASDAQ:SRRK) reported its financial results for the fourth quarter and full year of 2025, posting a net loss that was slightly narrower than analyst expectations but highlighting a year of significant investment ahead of a potential commercial launch. The company’s stock saw moderate pre-market trading activity following the announcement.
Earnings and Revenue Versus Estimates
For the quarter ending December 31, 2025, Scholar Rock, a clinical-stage biopharmaceutical company, reported no revenue, which was in line with analyst forecasts. The company’s net loss per share came in at $0.88. This figure compares to the consensus analyst estimate for a loss of $0.91 per share, representing a slight outperformance against expectations.
The key financial takeaways from the report are:
- Q4 2025 EPS: Reported -$0.88 vs. Estimated -$0.91
- Q4 2025 Revenue: Reported $0.0M vs. Estimated $0.0M
- Full-Year 2025 Net Loss: $377.9 million, compared to $246.3 million in 2024.
The increased annual loss reflects substantially higher operating expenses, particularly in general and administrative costs, which more than doubled year-over-year to $176.2 million. This surge is attributed to stock-based compensation and investments in building out the company’s commercial infrastructure in preparation for the potential launch of its lead drug candidate.
Market Reaction and Financial Position
In pre-market trading, SRRK shares were down approximately 3%. This muted negative reaction suggests the market had largely anticipated the reported financials, with the focus remaining squarely on the company's pipeline progress rather than its current lack of revenue. The company ended 2025 with $367.6 million in cash, cash equivalents, and marketable securities. This financial runway was recently bolstered by a new debt facility of up to $550 million from Blue Owl Capital, providing non-dilutive capital intended to support commercialization efforts and pipeline advancement.
Pipeline Progress and 2026 Outlook
The earnings release was dominated by updates on Scholar Rock's lead candidate, apitegromab, a potential treatment for spinal muscular atrophy (SMA). Management reiterated that 2026 is expected to be a transformative year, centered on navigating the regulatory pathway for apitegromab.
The most critical near-term milestones include:
- U.S. Regulatory Path: The company plans to resubmit its Biologics License Application (BLA) for apitegromab following a successful FDA reinspection of the Catalent Indiana fill-finish facility, which is being remediated by Novo Nordisk. A U.S. launch is anticipated upon approval, expected in 2026.
- European Review: A decision from the European Medicines Agency on the Marketing Authorisation Application is expected in mid-2026, with a launch planned for the second half of the year, starting in Germany.
- Pipeline Expansion: Development continues on a subcutaneous formulation of apitegromab and on SRK-439, a next-generation myostatin inhibitor. The company also plans to initiate a Phase 2 trial of apitegromab in facioscapulohumeral muscular dystrophy (FSHD) in mid-2026.
The company did not provide specific financial guidance for 2026 in the release. Analyst estimates currently project a continued net loss for the full year 2026, with the first sales potentially beginning to materialize.
Conclusion
Scholar Rock's fourth-quarter results underscore its status as a pre-commercial biotech, where financial losses are expected as the company invests heavily in its transition to a commercial-stage entity. The slight beat on EPS is a minor positive, but the investment thesis for SRRK remains almost entirely dependent on the successful regulatory approval and subsequent launch of apitegromab. The company's strengthened balance sheet provides it with the capital necessary to execute its key 2026 milestones. Investors will be closely monitoring the FDA's reinspection of the Catalent facility and the subsequent BLA resubmission as the next major catalysts.
For detailed historical earnings data and future analyst estimates, visit the Scholar Rock earnings and estimates page.
Disclaimer: This article is for informational purposes only and does not constitute financial or investment advice. The author has no position in any stock mentioned. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.
